Ranbaxy, Wockhardt flag off US generic market foray - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Sep 7, 2000 - Ranbaxy, Wockhardt flag off US generic market foray

Ranbaxy, Wockhardt flag off US generic market foray

Sep 7, 2000

The test for the Indian pharmaceutical companies in the generic markets is well and truly underway with Ranbaxy and Wockhardt launching their cardiovascular generic, enalapril maleate tablets a week back. This was subsequent to the expiry of the patent held by the US drug major, Merck. (The US sales of Merck's brand, Vasotec, in 1999 was US$ 806 Million, i.e. approximately Rs 36.82 bn). Even earlier while Ranbaxy and Wockhardt have launched ranitidine tablets, the fact was that these were mere test cases where the companies concerned were checking out their marketing set ups. In this case, Ranbaxy has doubled its production of enalapril tablets after the launch, which it claims was successful.

As far as marketing is concerned while Wockhardt, is marketing its product through Sidmak Laboratories, its US partner, Ranbaxy has used its own US subsidiary for marketing.

However, the prices of this drug are expected to drop almost 80%90% since the US FDA has approved ANDA's of 8 other companies.

Moreover, in anticipation of enalapril patent and exclusivity expiry, Merck has been promoting Lisinopril at the expense of enalapril. Ranbaxy has already filed its ANDA for Lisinopril whose patent expires in June 2002. (Lisinopril sales in 1999 were US$ 1215 million.)

How profitable the launch turns out for Ranbaxy will only be known when the company announces its third quarter results next month. We spoke to Wockhardt and the company has said that in a full year of production it would earn around US $ 23 mn.

Equitymaster requests your view! Post a comment on "Ranbaxy, Wockhardt flag off US generic market foray". Click here!


More Views on News

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

Jun 15, 2021

All you need to know about the IPO of Krishna Institute of Medical Sciences.

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

Jubilant Pharmova Drops 6% on Weak March Quarter Numbers (Views On News)

Jun 8, 2021

Here's a rundown on the latest quarterly results of Jubilant Pharmova.

Lupin Gains 16% in a Month. Here's Why it Could Rally More (Views On News)

Jun 4, 2021

Recent developments in digital healthcare and revised targets by brokerages send Lupin shares flying.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments (Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


Apr 1, 2015 (Close)


  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks